AOD-9604 progressed through six human clinical trials with more than 900 participants but failed to reach statistical significance in its Phase IIb obesity endpoint, and Metabolic Pharmaceuticals terminated development in 2007
Once this store has been depleted, however, deficiency symptoms slowly set in
Our customized peptide therapy programs are designed to target your unique needs, whether youre recovering from injury, managing inflammation, or supporting long-term gut health
Blended peptide compounds have an added quality challenge both active components have to meet purity specs, and the ratio has to be consistent batch to batch
This is why it carries a significantly better safety profile than direct HGH therapy
Reconstitution: 3.0 mL per 70 mg vial (23.3 mg/mL) for precise unit measurements